In a 2026 UK-based analysis, 2.9% of adults in Great Britain, about 1.6 million people, reported using a GLP-1 or GLP-1/GIP medicine for weight loss during the previous year. A further 1.7%, roughly 910,000 adults, used one exclusively for weight loss, while 4.5% had used a GLP-1-class medicine for any reason during that period, according to the peer-reviewed UK analysis. These figures explain why searches for GLP-1 medication UK now sit at the intersection of obesity care, diabetes treatment, private healthcare, NHS policy and medicine supply.
The important qualification is that widespread interest doesn't mean widespread NHS access. NICE approvals operate within clinical thresholds, specialist referral pathways and phased commissioning. Private prescribing can offer another lawful route, but it still requires a proper assessment, a valid prescription and continuing clinical oversight.
Reviewed by: UK healthcare professional
Review date: 18 August 2026
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any treatment.
Table of Contents
- How Widely GLP-1 Medications Are Now Used in the UK
- How GLP-1 Medications Work in the Body
- Approved GLP-1 Medications Available in the UK
- NHS Access and Why GLP-1 Treatment Remains Limited
- Private GLP-1 Prescribing and Online Pharmacy Safety
- Side Effects, Risks and Who Should Avoid GLP-1 Medications
- Supply Pressures and the Impact on Diabetes Patients
- Common Questions About GLP-1 Medication in the UK
How Widely GLP-1 Medications Are Now Used in the UK
GLP-1 use in the UK has risen sharply, but widespread interest has not translated into widespread NHS access. These medicines were first associated mainly with type 2 diabetes. Their role has since expanded because related biological pathways also influence appetite, food intake and body weight.
The scale of reported use is substantial. In the Great Britain analysis, 2.9% of adults had used a GLP-1 or GLP-1/GIP medicine to support weight loss in the previous year, equivalent to about 1.6 million people when extrapolated to the adult population. 1.7%, roughly 910,000 adults, had used one solely for weight loss, rather than for diabetes or heart disease. The analysis also recorded 4.5% using a GLP-1-class medicine for any reason, as detailed in the UK population analysis.
Reported use does not mean that everyone seeking treatment meets prescribing criteria. NHS treatment depends on clinical thresholds, relevant health conditions and the pathway available locally. Private prescribing also requires an assessment, a valid prescription and ongoing monitoring.
Demand has moved faster than access
NICE recommends obesity medicines alongside a reduced-calorie diet and increased physical activity. NHS services generally prioritise people with obesity and related health conditions, rather than providing injections as a general weight-loss product.
This produces the central UK access gap. Public demand is broad, while NHS prescribing and specialist capacity remain selective. Clinicians must protect continuity for people using GLP-1 medicines for diabetes, and private providers must apply the same basic safety principles despite offering a more direct route to assessment.
Practical rule: Popularity does not establish suitability. A regulated prescriber should review your medical history, current medicines, health risks and treatment goals before deciding whether a GLP-1 medicine is appropriate.
How GLP-1 Medications Work in the Body
GLP-1 medicines mimic naturally occurring incretin hormones, acting through three connected pathways: the pancreas, the stomach and the brain. Their effects influence blood glucose, digestion and appetite, which helps explain both their clinical uses and their common side effects.
In the pancreas, GLP-1 receptor agonists support insulin release when glucose rises after eating. Because this response is glucose-dependent, the medicines help the body manage blood sugar more effectively. This mechanism underpins their established role in type 2 diabetes.
In the stomach, GLP-1 medicines can slow gastric emptying, allowing food to pass into the intestine more gradually. Patients may feel full for longer, and a smaller meal may feel sufficient. The same effect can cause nausea, early fullness and changes in bowel habit, particularly when treatment begins or the dose increases.
The medicines also affect appetite regulation in the brain. Hunger signals and the salience of food may change, so persistent cravings become less intrusive for some people. Eating behaviour remains influenced by many factors, but GLP-1 treatment changes physiological signals involved in appetite rather than relying on willpower alone.
Tirzepatide is described as a dual incretin medicine because it acts on GLP-1 and GIP pathways. Semaglutide and liraglutide are GLP-1 receptor agonists. The appropriate option depends on its licensed indication, your clinical suitability, tolerability, other medicines and the monitoring available.
Adequate nutrition, hydration and physical activity still matter. GLP-1 treatment forms part of a broader weight-management plan and does not replace medical assessment or sustainable dietary support.
The following video offers a visual introduction to the biological pathway:
Approved GLP-1 Medications Available in the UK
Brand names matter because the same active ingredient can have different licensed uses, strengths and prescribing contexts. Ozempic and Wegovy both contain semaglutide, but they aren't interchangeable labels for every clinical purpose. Victoza and Saxenda contain liraglutide, while Mounjaro contains tirzepatide, a dual incretin medicine.
Semaglutide is used in diabetes care under the Ozempic brand and in weight management under Wegovy. NICE recommends semaglutide for weight management only with dietary and activity measures, within defined BMI and comorbidity criteria, and through specialist services. The recommendation also limits treatment to a maximum of 2 years, as set out in the NICE semaglutide recommendations.
Liraglutide is available as Saxenda for weight management and Victoza for type 2 diabetes. Unlike the commonly recognised weekly pen schedules, liraglutide is administered daily. Tirzepatide, sold as Mounjaro, has diabetes and weight-management uses, subject to the relevant licence and clinical pathway.
| Medication | Brand names | Licensed use | Administration |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | Ozempic for type 2 diabetes, Wegovy for weight management | Injectable pen, generally weekly |
| Liraglutide | Victoza, Saxenda | Victoza for type 2 diabetes, Saxenda for weight management | Injectable pen, daily |
| Tirzepatide | Mounjaro | Type 2 diabetes and weight management, subject to clinical criteria | Injectable pen, generally weekly |
The table is a starting point, not a treatment selector. Your prescriber needs to confirm the indication, dose, contraindications and supply position. For a plain-English explanation of semaglutide's uses, see what semaglutide is used for.
A prescription-only medicine isn't made safer by a familiar brand name. It should come from a lawful supply chain, with a clinician able to review the decision and respond if problems arise.
NHS Access and Why GLP-1 Treatment Remains Limited
NICE approval doesn't create automatic NHS access. It establishes that a treatment can be offered within specified clinical conditions, while NHS England and local services determine how implementation works in practice.
For tirzepatide, NICE recommends treatment alongside a reduced-calorie diet and increased physical activity for adults with an initial BMI of at least 35 kg/m² and at least one weight-related comorbidity. The recommendation also requires referral into a specialist overweight and obesity management service, as described in the NICE committee papers for tirzepatide.
The marketing-authorisation scope can include adults with a BMI of 30 kg/m² or more, or a BMI of 27 to 29.9 kg/m² with at least one weight-related comorbidity. Those licensing boundaries don't mean every person within them receives NHS treatment. NICE's treatment-pathway information distinguishes the authorised scope from the more restricted NHS recommendation.
What the pathway looks like
A typical NHS route starts with primary care or another healthcare professional identifying obesity-related risk and considering referral. A specialist service then assesses suitability, provides dietary and activity support, reviews coexisting conditions and decides whether medication belongs in the treatment plan.
Rollout is phased. NHS England's interim commissioning guidance links Cohort II to Year 2, 2026/27 implementation, so timing can depend on local organisation and the cohort into which a patient falls. NHS-facing commentary expects fewer than 50,000 people a year to receive treatment by 2028, a figure far below the number of adults who may meet clinical criteria, as summarised in the verified access-gap data.
The NHS states that from 23 March 2025, Mounjaro for weight management may be prescribed only by a specialist weight management service, where a healthcare professional considers it the right treatment. The NHS weight-management injection guidance makes the specialist route explicit.
Local referral arrangements, capacity and waiting times can differ. A private consultation may be quicker, but it doesn't remove eligibility checks, clinical risk assessment or the need for follow-up.
Private GLP-1 Prescribing and Online Pharmacy Safety
Private prescribing follows the same basic safety principle as any other prescription-only treatment. A clinician assesses whether the medicine is suitable, issues a prescription only when clinically justified, and a lawful pharmacy dispenses it.
The NHS Specialist Pharmacy Service states that GLP-1 receptor agonists are prescription-only medicines in the UK. They should be supplied through a lawful mechanism, such as a valid prescription from a qualified prescriber. A website offering direct purchase without an appropriate clinical process isn't equivalent to a regulated online pharmacy.
What a proper consultation should establish
A safe online consultation shouldn't be a superficial questionnaire designed to approve everyone. It should gather enough information for a prescriber to make a defensible decision.
- Medical history: This includes weight-related conditions, previous treatment, relevant gastrointestinal problems and other factors affecting suitability.
- Current medication: The prescriber needs to consider diabetes medicines and possible interactions, as well as whether another clinician is already managing your care.
- Treatment objective: Weight management and diabetes treatment aren't identical indications, even where medicines share an active ingredient.
- Follow-up arrangements: You should know how to report side effects, ask questions and receive reviews after treatment begins.
Check that the pharmacy is regulated by the GPhC, that the prescriber is appropriately registered, and that the medicine is dispensed by the named pharmacy rather than sent from an unexplained third party. You should also receive clear information about storage, delivery, dosing, missed doses and urgent symptoms.
An online pharmacy can be convenient, but convenience isn't the clinical safeguard. The safeguard is a documented assessment followed by ongoing access to qualified support. XO Medical is one example of a UK-registered online pharmacy and telehealth service that provides online consultations for prescribed treatments. You can read its educational guidance on how a regulated online pharmacy works in the UK.
Side Effects, Risks and Who Should Avoid GLP-1 Medications
The most common problems are gastrointestinal. Patients may experience nausea, vomiting, diarrhoea, constipation, abdominal discomfort or reduced appetite. These effects can be more noticeable when treatment starts or when the dose increases, which is why gradual prescribing and review matter.
Some symptoms settle as the body adjusts, but persistent or severe symptoms need clinical attention. Repeated vomiting or diarrhoea can contribute to dehydration, while significant abdominal pain requires assessment rather than being dismissed as an expected nuisance.
Situations requiring particular caution
A prescriber will consider whether the medicine is appropriate in light of:
- Pregnancy or planned pregnancy: Weight-management medicines aren't suitable to start or continue casually in this context. Discuss contraception, pregnancy planning and stopping treatment with a qualified clinician.
- Breastfeeding: The decision requires individual clinical assessment.
- Previous pancreatitis or significant abdominal symptoms: The history may affect suitability and monitoring.
- Severe gastrointestinal disease: Delayed gastric emptying can be clinically important for some patients.
- Personal or family history of medullary thyroid carcinoma or MEN 2: This must be disclosed during assessment.
- Allergy or hypersensitivity: A known reaction to the active ingredient or formulation is relevant to prescribing.
These aren't a complete list of contraindications or precautions. Your clinician also needs to review diabetes treatment, kidney health, eating-disorder history and any planned procedures where gastric emptying could matter.
Safety comes before speed: A service that approves treatment without asking about your medical history isn't offering a safer form of access.
Patients should seek prompt medical advice for severe or unusual symptoms, especially persistent vomiting, severe abdominal pain, symptoms of an allergic reaction or signs of dehydration. XO's educational overview of weight-loss injections and their safety considerations can help you prepare questions, but it can't replace an assessment.
Supply Pressures and the Impact on Diabetes Patients
GLP-1 demand affects more than people seeking weight management. Diabetes patients may rely on these medicines for blood sugar control, and interruptions can create clinical problems. Diabetes UK explains that the global shortage was partly driven by off-label semaglutide prescribing for weight loss, which increased demand beyond available supply, in its incretin-mimetic shortage FAQs.
This creates an ethical question for private healthcare. If a person uses a GLP-1 privately for weight loss, are they worsening access for someone with diabetes? The answer isn't reducible to blaming individual patients. Supply chains, licensing, prescribing decisions and stock management all shape availability, but responsible prescribers still need to recognise the wider consequences of demand.
How responsible services manage the tension
NHS-facing updates have advised that weight-loss prescribing should begin only when supply is sufficient to avoid affecting people already using treatment for diabetes. Diabetes UK also records that exenatide, sold as Bydureon, was discontinued and supplies were no longer available in October 2025, demonstrating that supply problems can involve product discontinuation as well as temporary shortages.
One 2026 update reported that Wegovy was available in the UK, while supply remained managed and limited, according to the verified shortage information. The MHRA also issued updated prescriber guidance in January 2026, showing that safety oversight and prescribing scrutiny continue alongside availability concerns.
A careful private service should avoid encouraging stockpiling, should dispense only against a valid prescription and should ask whether the patient already receives diabetes care elsewhere. Patients shouldn't switch, ration or stop diabetes medicines without speaking to their treating team.
The practical standard is simple. Weight-management expansion mustn't undermine continuity of diabetes treatment, and patients deserve honest information when a preferred product isn't available.
Common Questions About GLP-1 Medication in the UK
How long can NHS semaglutide treatment continue?
NICE recommends semaglutide for weight management alongside dietary and activity measures, within specialist multidisciplinary care, for a maximum of 2 years. That doesn't mean every patient automatically receives the full period, or that treatment must stop without a review. The specialist team should assess response, tolerability, health priorities and what support is needed afterwards.
Are BMI thresholds different for some ethnic groups?
Yes. NICE notes that lower BMI thresholds are usually used for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, with thresholds generally reduced by 2.5 kg/m². This reflects differences in cardiometabolic risk at a given BMI and should be applied as part of a full clinical assessment, not as a self-prescribing calculation. The relevant details appear in NICE's prescribing guide for overweight and obesity medicines.
Can GLP-1 medicines be used long term?
Some people may need continuing weight-management support, but the appropriate duration depends on the specific medicine, licensed indication, response and prescriber review. NHS and private treatment plans shouldn't promise indefinite use. If treatment is stopped, appetite and weight may change, so your clinician should discuss maintenance strategies rather than treating discontinuation as the end of care.
What should I eat while taking a GLP-1 medicine?
Aim for nourishing, manageable meals and adequate fluids, while following the plan provided by your clinician or dietitian. A practical meal-planning resource such as AI Meal Planner GLP-1 may help organise ideas, but it isn't a substitute for individual dietary advice, particularly if you have diabetes, gastrointestinal symptoms or a history of disordered eating.
Is a private online prescription automatically safe?
No. Safety depends on the prescriber, the quality of the assessment, the pharmacy's regulation, the medicine's source and the follow-up available. Look for a UK-registered pharmacy regulated by the GPhC, a valid prescription-only process and clear access to clinical support.
If you're considering GLP-1 treatment, XO provides UK online consultations through a registered pharmacy service, with clinician assessment before prescribed medication is supplied. You can use the consultation to discuss eligibility, risks, medicine choice and the practical differences between NHS and private care.
0 comments